Yu Li
State Key Laboratory Of Oncology In South China, No. 651 Dongfeng Road East
Guangzhou, 510060, China
Guangzhou, 510060, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Erratum for: Contrast-Enhanced US Using Perfluorobutane for Diagnosing Small HCC in High-Risk Patients: Comparison with MRI LI-RADS Version 2018.
Journal: Radiology
Published: April 28, 2026
Contrast-Enhanced US Using Perfluorobutane for Diagnosing Small HCC in High-Risk Patients: Comparison with MRI LI-RADS Version 2018.
Journal: Radiology
Published: March 03, 2026
HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation-Mediated TXNRD1 Stabilization to Suppress Ferroptosis.
Journal: Cancer research
Published: January 20, 2026
COLEC12high tumor-associated macrophages orchestrate lenvatinib resistance and cancer stemness in hepatocellular carcinoma via paracrine NRG1-HER2/HER3 signaling.
Journal: Clinical and molecular hepatology
Published: September 26, 2025
Combination of CT/MRI LI-RADS With Second-Line Contrast-Enhanced Ultrasound Using Sulfur Hexafluoride or Perfluorobutane for Diagnosing Hepatocellular Carcinoma in High-Risk Patients.
Journal: Korean journal of radiology
Published: September 02, 2024
MAF1 suppresses AKT-mTOR signaling and liver cancer through activation of PTEN transcription.
Journal: Hepatology (Baltimore, Md.)
Published: October 26, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026